Clinical Trials Browser

NCT05312840 2026-06-01

Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Sintilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer

Phase 4 Completed

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07279935 2026-06-01

REVIVE

Phase 4 Recruiting

100 enrolled

Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT07405086 2026-05-22

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Phase 4 Recruiting

160 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

Clinical Trials

Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Sintilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer

REVIVE

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

PROMETHEE

Dabrafenib and/or Trametinib Rollover Study

GASTIVA

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Crizotinib Continuation Clinical Study

AmiCARE

EPITOP-01

Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)

Lorlatinib Continuation Study

GPS

Keynote-593

CROWD

TAIL

WAVE

IMPROVE-I

Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX

Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLC

OSIBOOST 2

ADAPT ALEC

Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC

ROSIE

PILOT

Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations

PCG

SELECT-2

ON TRAX

TEMPLE-2

BUDDY

IMPROVE-II

IMPROVE-III

Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in Elective VATS-Lobectomy for NSCLC

Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC

Dexamethasone, Flurbiprofen Axetil and Delirium After Lung Cancer Surgery

Osimertinib Study in Indian Patients

PKAPIR

Study of Nivolumab for Advanced Cancers in India

Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.

Oncoxin® and Quality of Life in Cancer Patients

Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery

Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

ABOUND 70+

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.